Bragar Eagel & Squire Reminds Atara Investors of Lawsuit Deadline

Investors have until May 22nd to seek lead plaintiff role in class action against biotech firm.

Apr. 17, 2026 at 4:20pm

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a stack of legal documents, a pen, and a calculator arranged on a clean, monochromatic background, symbolizing the abstract concepts of corporate litigation, regulatory scrutiny, and financial risk.A legal case against Atara Biotherapeutics alleges the company misled investors about manufacturing and regulatory issues.NYC Today

Bragar Eagel & Squire, P.C., a national stockholder rights law firm, announced that a class action lawsuit has been filed against Atara Biotherapeutics, Inc. (NASDAQ:ATRA) in the U.S. District Court for the Central District of California. The lawsuit alleges that Atara made false and misleading statements about its business, operations, and prospects related to its tabelecleucel Biologics License Application and ongoing clinical trials.

Why it matters

The lawsuit claims Atara overstated the regulatory prospects for its tabelecleucel drug and failed to disclose manufacturing issues and deficiencies in a key clinical study that made FDA approval unlikely. This could have a significant negative impact on Atara's business and financial condition.

The details

The lawsuit alleges that Atara: (i) failed to disclose manufacturing issues and deficiencies in the ALLELE study that made FDA approval of tabelecleucel unlikely; (ii) accordingly, overstated the regulatory prospects for tabelecleucel; and (iii) the manufacturing issues also subjected Atara to heightened regulatory scrutiny and jeopardized its ongoing clinical trials.

  • The class period is from May 20, 2024 to January 9, 2026.
  • Investors have until May 22, 2026 to apply to the court to be appointed as lead plaintiff.

The players

Bragar Eagel & Squire, P.C.

A nationally recognized stockholder rights law firm that filed the class action lawsuit against Atara Biotherapeutics.

Atara Biotherapeutics, Inc.

A biopharmaceutical company developing novel immunotherapies for patients with cancer and other serious medical conditions.

Got photos? Submit your photos here. ›

What they’re saying

“If you purchased or otherwise acquired Atara shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato.”

— Brandon Walker, Litigation Partner, Bragar Eagel & Squire

What’s next

Investors have until May 22, 2026 to apply to the court to be appointed as lead plaintiff in the lawsuit.

The takeaway

This lawsuit highlights concerns about Atara's transparency regarding manufacturing issues and clinical trial data that could impact the regulatory prospects for its lead drug candidate. Investors will be closely watching how this case unfolds and its potential implications for the company's future.